Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Metastasis of Colon Carcinoma Cells Depends on a TGF-beta Signaling Protein

By LabMedica International staff writers
Posted on 03 Jan 2013
Cancer researchers have linked the transforming growth factor-beta (TGF-beta) receptor-interacting protein km23-1 to the ability of human colon carcinoma cells to migrate and metastasize.

Previous studies had shown that km23-1, a member of an ancient superfamily of NTPase-regulatory proteins, was a TGF-beta receptor-interacting protein that played an important role in TGF-beta signaling. More...


To further elucidate the function of km23-1, investigators at the Pennsylvania State College of Medicine (Hershey, USA) identified its novel protein interacting partners by using tandem affinity purification (TAP) and tandem mass spectrometry (MS).

Results published in the November 23, 2012, issue of the journal Biochemical and Biophysical Research Communications revealed that km23-1 interacted with a class of proteins involved in actin-based cell motility and modulation of the actin cytoskeleton. Km23-1 modulated the formation of a highly organized stress fiber network. Knockdown (KD) of km23-1 decreased RhoA activation in Mv1Lu epithelial cells. RhoA (Ras homolog gene family, member A) is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. This protein is essential for the signaling function of the Rho GTPase complex. Previous studies have shown that in breast cancer increased RhoA activity stimulated cancer cell invasiveness and spreading, while RhoA deficiency suppressed cancer growth and progression. In addition to its role in breast cancer, imbalance in Rho GTPase activity has been implicated in other human diseases, including various cancers and neurological disorders.

The results of the current study demonstrated for the first time, according to the investigators, that depletion of km23-1 inhibited cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays.

"Cell migration is an important aspect of the process of a tumor spreading," said senior author Dr. Kathleen Mulder, professor of biochemistry and molecular biology at the Pennsylvania State College of Medicine. "Changes in this process transform tumor cells from local, noninvasive, confined cells to the migrating, metastatic cancer cells. By knowing that RhoA activity was decreased when km23-1 was reduced, we infer that km23-1 is needed for the regulation of these switches and has a role in cell movement. By inhibiting km23-1, you inhibit events that contribute to the cells spreading to other parts of the body."

Related Links:
Pennsylvania State College of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.